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Abstract
This Phase 1, randomized, two-site (United States), double-blind, placebo-controlled study enrolled 18 sexually abstinent
men and women. All received a single 300-mg dose of oral tenofovir disoproxil fumarate (TDF) and were then randomized
2:1 to receive single and then seven daily rectal exposures of vaginally-formulated tenofovir (TFV) 1% gel or a hydroxyethyl
cellulose (HEC) placebo gel. Blood, colonic biopsies and rectal and vaginal mucosal fluids were collected after the single oral
TDF, the single topical TFV gel dose, and after 7 days of topical TFV gel dosing for extracellular analysis of TFV and
intracellular analysis of the active metabolite tenofovir diphosphate (TFVdp) in peripheral blood mononuclear cells (PBMCs)
and isolated mucosal mononuclear cells (MMC), including CD4+ and CD4- cell subsets. With a single rectal dose, TFV plasma
concentrations were 24–33 fold lower and half-life was 5 h shorter compared to a single oral dose (p = 0.02). TFVdp
concentrations were also undetectable in PBMCs with rectal dosing. Rectal tissue exposure to both TFV and TFVdp was 2 to
4-log10 higher after a single rectal dose compared to a single oral dose, and after 7 daily doses, TFVdp accumulated 4.5 fold
in tissue. TFVdp in rectal tissue homogenate was predictive (residual standard error, RSE = 0.47) of tissue MMC intracellular
TFVdp concentration, with the CD4+ cells having a 2-fold higher TFVdp concentration than CD4- cells. TFV concentrations
from rectal sponges was a modest surrogate indicator for both rectal tissue TFV and TFVdp (RSE = 0.67, 0.66, respectively)
and plasma TFV (RSE = 0.38). TFV penetrates into the vaginal cavity after oral and rectal dosing, with rectal dosing leading to
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higher vaginal TFV concentrations (p,0.01).
Trial Registration: ClinicalTrials.gov NCT00984971
Introduction
Both topical and oral tenofovir (TFV)-containing regimens have
demonstrated efficacy in HIV prevention. TFV 1% gel demon-
strated 39% protective efficacy in women using the gel within
12 hours before and after sexual activity in the Centre for the
AIDS Programme of Research in South Africa (CAPRISA) 004
study [1]. The fixed dose combination of tenofovir disoproxil
fumarate (TDF)/emtricitabine (Truvada) prescribed daily in a
population of men who have sex with men in the iPrEx study
provided 44% protection against HIV infection [2]. Daily dosing
of TDF or Truvada provided 62 to 73% protection against HIV
transmission in serodiscordant men and women enrolled in the
Partners PrEP Study [3]. Furthermore, daily dosing of oral TDF
provided 49% reduction in HIV incidence rates among IV drug
users [4]. In both CAPRISA 004 and iPrEx, the level of protection
was related to drug exposure and adherence [1,2,5,6].
The primary objective of the Phase 1 RMP-02/MTN-006
clinical trial was to evaluate the systemic safety of TFV 1% gel
when applied rectally [7]. Built into this study was a comprehen-
sive pharmacokinetic evaluation comparing systemic and com-
partmental pharmacokinetics among oral TDF and rectal TFV
1% gel users. These novel within-subject pharmacokinetic analyses
were also used in an ex-vivo biopsy HIV challenge model to
correlate TFVdp exposure with protection against ex vivo
infection (reported in accompanying paper: Richardson-Harman
et al.) [7]. This is the first study to quantify human rectal mucosal
pharmacokinetics after topical administration of tenofovir in
multiple compartments concurrently, to compare it to exposure
after oral administration and to determine whether less-invasive
indicators of TVFdp concentrations in tissue CD4+ cells emerge,
potentially playing a future role in large clinical trials.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The trial was IRB-approved at each site (UCLA IRB in Los
Angeles, CA; University of Pittsburgh IRB, Committee C in
Pittsburgh, PA); all participants provided written informed
consent. RMP-02/MTN-006 is registered at ClinicalTrials.gov
(#NCT00984971) and is in compliance with the CONSORT
2010 trial reporting recommendations (www.consortstatement.
org).
Study Participants
Study participants were healthy HIV-1-seronegative men and
women with a history of consensual rectal anal intercourse, willing
to abstain from vaginal and rectal sex during active protocol
phases. Female participants were required to be using an
acceptable form of contraception (e.g., barrier method, IUD,
hormonal contraception, surgical sterilization, or vasectomization
of male partner).
Study Design
The pharmacokinetic component of the RMP-02/MTN-006
trial was designed to compare systemic and compartmental
pharmacokinetics among single oral TDF dosing (300 mg), and
single as well as multiple doses of rectally-applied vaginally-
formulated TFV 1% gel. This was a Phase 1, double-blind,
randomized, placebo-controlled comparison of oral TDF
(300 mg), rectally applied TFV 1% gel, and the hydroxyethyl
cellulose (HEC) placebo gel, the design of which has been
previously published [7], and is illustrated in Figures 1, 2.
Briefly, in this three-stage trial, all participants received a single
dose of oral TDF followed 4 weeks later by rectally applied TFV
1% gel or the HEC gel given as a single dose, and 4 weeks later,
seven daily doses of the same product previously administered
rectally. After enrollment, each subject was assigned to either the
treatment or placebo arm (2:1; TFV 1% gel:HEC gel) and also to
one of two post-exposure biopsy sampling arms (groups ‘‘A’’ and
‘‘B’’) to ensure mucosal safety. This limited the number of
sigmoidoscopic procedures per participant to three sigmoidoscopic
procedures in each of the first two study stages (single oral, single
rectal) with several days delay between biopsy collections for
mucosal healing. A single sigmoidoscopy biopsy collection point
was used following the 3rd stage (7-day rectal exposures). All
subjects provided biopsies (and other compartment samples) 0.5 h
after their dose of oral TDF or single/7-day dose of TFV gel. For
the single oral and single rectal exposures, in addition to all
subjects being sampled at 0.5 h, Group ‘‘A’’ subjects were also
biopsied on days 1 (24 hr) and 7; Group ‘‘B’’ subjects were also
biopsied on days 4 and 10. Participants were allowed a 2 day visit
window for this sampling but nearly all were seen on the first day
of their 3-day window. Just prior to each biopsy sample, blood
samples were obtained for plasma and peripheral blood mononu-
clear cell isolation, and rectal and vaginal mucosal fluids were
collected by sponge. Each 2 weeks of biopsy sampling was followed
by a 2-week resting period. The sample size (N = 18) was based on
a similar phase 1 study of topical microbicide UC781. [8] The
study was conducted from November 2009 to July 2010.
Pharmacokinetic Procedures for Single Oral and Topical
Dosing. All participants had blood plasma, PBMCs, and vaginal
and rectal fluid obtained before single oral and rectal dosing.
Additionally, 30 minutes after the dose, blood plasma, PBMCs,
rectal biopsies, rectal fluid and vaginal fluid samples were
obtained. At 2, 4, and 24 h after the dose, blood plasma, PBMCs,
and rectal/vaginal fluid samples were obtained. Subsequently, on
either days 1 and 7 (Group A) or 4 and 10 (Group B) post-dose,
blood plasma, PBMCs, rectal biopsies, rectal/vaginal fluid were
obtained.
Figure 1. Study Design.
doi:10.1371/journal.pone.0106196.g001
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Pharmacokinetic Procedures for Multiple Topical
Dosing. Thirty minutes after the 7th rectal dose of gel
(observed), blood plasma, PBMCs, rectal biopsies, rectal fluid
and vaginal fluid samples were obtained. At 2, 4, and 24 h after
the dose, blood plasma, PBMCs, rectal fluid, and vaginal fluid
samples were obtained.
Study Products
TDF tablets (300 mg) were supplied by Gilead Sciences (Foster
City, CA). TFV 1% gel and HEC gel were supplied by CONRAD
(Arlington, VA). TFV 1% gel (weight/weight) is tenofovir (PMPA,
9-[(R)-2-(phosphonomethoxy)propyl]adenine monohydrate), for-
mulated in purified water with edetate disodium, citric acid,
glycerin, methylparaben, propylparaben, and hydroxyethyl cellu-
lose with pH adjusted to 4–5 with an osmolarity of 3111 mOsmol/
kg. The HEC placebo gel contained hydroxyethyl cellulose as the
gel thickener, purified water, sodium chloride, sorbic acid, and
sodium hydroxide. The gel was isotonic with a pH of 4.4,
osmolarity of 304 mOsmol/kg, 24 and viscosity similar to the
other microbicide gel candidates. Both TFV and HEC gels were
prefilled into single-use, opaque applicators (HTI Plastics, Lincoln,
NE) containing 4 ml of gel.
Sample Processing
Plasma was collected in tubes containing EDTA anticoagulant.
Samples were centrifuged at 800 g for 10 minutes at 4uC, plasma
aliquoted into cryovials, and stored at 270uC. Peripheral blood
mononuclear cells (PBMCs) were isolated via centrifugation from
cell preparation tubes (CPT) at 1,8006g for 25 min at 28uC.
PBMCs were collected from the buffy coat and washed twice with
normal saline at room temperature (,21uC). Cells were
resuspended in 1 ml normal saline for cell counting. Cell pellets
were lysed with 70% methanol and stored at 280uC until analysis.
To release cells for intracellular analysis from colonic tissue,
biopsies were incubated with a dissociative enzyme cocktail
consisting of collagenase (0.5 mg/ml, Sigma-Aldrich, St. Louis,
MO), DNase I (0.083 U/ml, Roche, Indianapolis, IN), elastase
(0.07 U/ml, Worthington Biochemicals, Lakewood, NJ), and
hyaluronidase (0.4 U/ml, Worthington Biochemicals, Lakewood,
NJ). The digestions were carried out in RPMI with 7.5% FBS in
50 ml-conical tubes at 37uC with agitation (Invitrogen, Carlsbad,
CA) as previously described. [9,10] Cells were counted using
Guava/Millipore EasyCyte Plus (Millipore, Billerica, MA).
CD4+ T cells from tissue and PBMCs were isolated via positive
selection with CD4 microbeads using magnetic affinity column
separation (MACS) according to the manufacturer’s recom-
mended protocol (Miltenyi Biotec, Auburn, CA). CD4-positive
and CD4-negative fractions were collected for cell counting and
intracellular drug analysis. We used PBMCs to test for changes in
intracellular TFV-DP concentrations as a result of tissue cell
extraction and cell subset isolation compared to typical PBMC
preparation. Compared to usual PBMC processing, there was no
difference in PBMC TFV-DP concentrations resulting from the
tissue digestion cocktail, monoclonal antibody incubation, or
running cells over the MACS column.
Sample Analysis
All TFV and TFVdp concentrations were measured using
validated LC–MS/MS methods. Total numbers of samples
analyzed were as follows: 275 blood plasma, 460 PBMCs, 205
tissue homogenates, 98 isolated mononuclear cells, 99 CD4+ cells,
99 CD4- cells, 264 rectal sponges, 54 vaginal sponges [11]. Briefly,
TFV and TFVdp concentrations were determined by previously
described LC-MS/MS methods [12,13] validated for all matrices
by the Johns Hopkins Clinical Pharmacology Analytical Labora-
tory. TFV and TFVdp assays meet the FDA bioanalysis guidance
values of # 615% for precision and accuracy [14]. All calibrators
were prepared using analyte calibrator stock solution diluted in the
relevant human biological matrix corresponding to the samples to
be assayed (plasma, PBMC lysate, cervicovaginal fluid, rectal fluid,
homogenized colon or vaginal tissue). Thawed aliquots of plasma
and tissue homogenate with 13C-TFV internal standard were
protein precipitated with methanol. Vaginal and rectal fluid
sponges were eluted in 50:50 methanol:water mixture. Sponges
were weighed both before and after. Aliquots, also with 13C5-TFV
internal standard, underwent solid phase extraction using HLB
oasis cartridges. The supernatants and eluants were collected,
dried, and reconstituted in 0.5% acetic acid for analysis. For
chromatographic separation of samples, a gradient elution with a
Zorbax Eclipse XDB-C18 column, with positive electrospray
Figure 2. Sample Collection. All 18 trial participants received a single oral dose of 300 mg TDF followed by intensive 24 h PK. After ,2 week
resting period, 12 subjects were randomized to receive a single rectal gel dose of 1% TFV gel with intensive 24 h PK followed, after ,2 week resting
period, by 6 sequential, daily, self-administered rectal 1% TFV gel doses with the 7th dose administered in-clinic with subsequent 24 h intensive PK.
doi:10.1371/journal.pone.0106196.g002
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ionization (ESI) was used, with detection via multiple reaction
monitoring using a LC-MS/MS system (Waters Acquity UPLC
and Agilent 1100 HPLC Applied Biosystems API4000 mass
spectrometer). Calibration standards for the TFV assay ranged
from 0.31 to 1,280 ng/ml (0.25–50 ng/sample for tissue).
For intracellular TFVdp analysis, tissue homogenates and
isolated cell lysates were analyzed using an indirect assay [13].
Table 1. Demographics.
Oral tenofovir Tenofovir Gel HEC placebo gel
N 18 12 6
Age (mean, STD) 42.1 (11.4) 41.3 (11.9) 43.7 (10.2)
Gender: M 14 (78%) 10 (83%) 4 (67%)
Gender: F 4 (22%) 2 (17%) 2 (33%)
Latino or Hispanic Origin: Y 5 (28%) 3 (25%) 2 (33%)
Latino or Hispanic Origin: N 13 (72%) 9 (75%) 4 (67%)
Race: Black or African-American 2 (11%) 1 (8%) 1 (17%)
Race: White 15 (83%) 10 (84%) 5 (83%)
Race: Other 1 (6%) 1 (8%) 0
doi:10.1371/journal.pone.0106196.t001
Table 2. Noncompartmental Pharmacokinetic Parameters (*Insufficient data to perform NCA on CD4- and CD4+ PBMC; see
companion publication Richardson-Harmon et.al for exposure-response analysis; **Composite Profile).
Matrix Analyte, PK parameter
Single Oral Dose,
median (min–max); N
Single Rectal Dose
median (min–max); N
Multiple Rectal Dose
median (min–max); N
Plasma TFV T1/2 (h) 10.8 (6.82–19.2); 18 4.56 (2.61–62.9); 12 6.62 (4.55–32.1); 10
TFV AUC24 h (ng/mL6h) 2210 (1100–2940); 18 66.3 (12.4–114); 12 46.5 (17.1–178); 10
TFV Cmax (ng/mL) 252 (76.8–387); 18 10.5 (5.08–33.4); 12 8.61 (2.37–11.2); 10
TFV Tmax (h) 1.93 (0.267–3.92); 18 0.317 (0.183–1.98); 12 0.258 (0.183–2.03); 10
PBMC (total)1 TFVdp AUC24 h (fmol/10‘6 cells6h) 4.26 (0.240–389) 0.24 (0.24–0.24) 0.24 (0.24–0.24)
TFVdp Cmax (fmol/10‘6 cells) 0.375 (BLQ–38.6) BLQ (BLQ–0.01) BLQ (BLQ–0.01)
Rectal Tissue TFV AUC24 h (ng/mg6h)* 0.790 70.4
TFVdp AUC24 h (fmol/mg6h)** 0.240 5470
TFV C24 h (ng/mg) 0.06 (BLQ–0.360) 0.06 (BLQ–12.6)
TFVdp C24 h (fmol/mg) BLQ (BLQ–991) 285 (BLQ–490)
Accumulation Ratio, TFV 2.03
Accumulation Ratio, TFdp 4.48
TFV C30 min (ng/mg) 5.81 (BLQ–95.1); 12 11.8 (BLQ–430); 11
TFVdp C30 min (fmol/mg) 176 (BLQ-1230); 12 789 (55.7–7190); 12
Rectal Mononuclear Cells TFVdp C30 min (fmol/10‘6 cells) BLQ (BLQ–BLQ); 18 454 (BLQ–1460); 12 1324 (BLQ–13900); 11
TFVdp C24 h (fmol/10‘6 cells) BLQ (BLQ–524); 8 228 (BLQ–290); 3
TFVdp CD4+ C30 min (fmol/10‘6 cells) BLQ (BLQ–BLQ); 18 266 (BLQ–3950); 12 1080 (BLQ–31200); 12
TFVdp CD4+ C24 h (fmol/10‘6 cells) 26.7 (BLQ–724); 18 250 (BLQ–1110); 3
TFVdp CD4- C30 min (fmol/10‘6 cells) BLQ (BLQ–20); 18 112 (BLQ–1340); 12 330 (BLQ–12000); 12
TFVdp CD4- C24 h (fmol/10‘6 cells) 28.4 (BLQ–157); 8 92.7 (BLQ–265); 3
Rectal Fluid TFV AUC24 h (ng/g6h,610‘5) 1.03 (0.00265–15.1); 16 11.0 (1.56–42.5); 12 7.03 (1.49–32.6); 7
TFV Cmax (ng/g,610‘4) 0.978 (0.00179–15.1); 17 73.9 (8.79–297); 12 41.6 (10.1–87.2); 7
TFV Tmax (h) 24 (0.330–24.5); 4 0.380 (0.300–2.08); 12 0.330 (0.280–0.370); 7
Vaginal Fluid TFV AUC24 h (ng/g6h) 2.33 (0.979–2.72); 4 1.43 (0.587–2.27); 2 11.8; 1
TFV Cmax (ng/g,610‘4) 0.134 (0.0515–0.182); 4 0.313 (0.0432–0.582); 2 0.696; 1
TFV Tmax (h) 3.01 (1.92–24); 4 2.74 (1.62–3.87); 2 3.58; 1
*Insufficient data to perform NCA on CD4- and CD4+ PBMC; see companion publication Richardson-Harmon et.al for exposure-response analysis.
**Composite Profile.
doi:10.1371/journal.pone.0106196.t002
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TFVdp was isolated from cell lysates on a Waters QMA cartridge
(Waters Corporation, Milford, MA) over a salt (KCl) gradient.
TFV and tenofovir monophosphate (TFVmp) were separated
from the cartridge under lower salt concentrations followed by
elution of TFVdp with application of 1 M KCl to the cartridge.
Isolated TFVdp was then enzymatically dephosphorylated to TFV
via phosphatase digestion with incubation with phosphatase and
13C-TFV internal standard. TFV was isolated from the KCl
solution using trifluoroacetic acid and eluted in methanol. TFV
with 13C-TFV internal standard was analyzed via UPLC-MS/MS
mass spectrometer as described above.
Pharmacokinetic and Statistical Analysis
Data Standardization
All values below the limit of quantification (BLQ) were imputed to
be 0.01 for noncompartmental pharmacokinetic analysis (NCA) for
all arms except rectal administration of placebo. Concentration data
during rectal administration for the placebo arm is excluded from
this report. All sponge concentrations (ng/sponge) were normalized
to fluid weight on sponge (g) by division, resulting in units of ng/g.
Data are presented as median (range) unless otherwise noted.
PK Parameter Calculations
Actual time after dosing was used for NCA. When calculating
individual pharmacokinetic (PK) parameters (Cmax, Tmax,
AUC24 h, half-life), only profiles with: a) greater than two data
points, b) last concentration time point less than or equal to 24 h,
and c) first concentration time point less than or equal to 12 h
were used. A composite PK profile was constructed for rectal tissue
homogenates using the median concentrations from all subjects at
each nominal time point, regardless of the actual time. In this case,
PK parameters were calculated based on this composite profile
with nominal times. Composite profiles must be calculated with
protocol-specified nominal times because descriptive statistics
cannot be calculated with actual times; there were minor
deviations in sample collection time during the trial, as it is
impossible to collect at the exact protocol-specified time. For
calculating AUC24 h, linear interpolation was used to interpolate
the concentration at 24 h if the actual time was greater than 24 h.
If actual time was between 22 h and 24 h, then that concentration
was imputed to be the 24 h concentration. Half-life estimation was
performed by choosing points during the beta-phase of the
elimination slope. (3 single rectal dose plasma PK profiles
contained an imputed value of 0.01 at the 24 h timepoint.)
Parameter calculation was performed with Phoenix WinNonlin
6.3.0.395 (Certara/Pharsight). Data manipulation and plotting
was performed with R 2.15.10 [15] with libraries: lattice [16],
latticeExtra [17], plyr [18] and reshape2 [19].
Accumulation ratio for rectal dosing was defined in one of two
ways: either the AUC24 h ratio of multiple dose gel to single dose
gel, or if unavailable, the 0.5 h concentration ratio of multiple dose
gel to single dose gel.
Statistical Analysis
Robust linear regression was carried out with robust package for
R [20], and fitted to the model: DV = b0+b16IV+b26CV+
b36IV6CV. Dependent (DV) and independent variables (IV) are
Figure 3. TFV Plasma Half-life is shorter (p =0.02) during rectal administration. Plasma concentration-time profile is shown (median and
interquartile range). Nominal time for single rectal dose was shifted right by 0.250 h and multiple rectal dose by 0.500 h for clarity. N = 18 for oral
dose, 12 single rectal dose, 12 multiple rectal dose. (BLQ values are imputed as 0.01.)
doi:10.1371/journal.pone.0106196.g003
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continuous, while categorical variable (CV) is either 0 or 1. Any
parameter terms with p.0.05 were dropped and excluded from
the statistical model, and re-fitted with a simpler model (backward
elimination). All robust linear regression was performed with log10-
transformed concentration data. Robust linear regression allows
for differential weights to datapoints in respect to outlier datapoint;
outliers were given less weight. This results in a more stable model.
[21] All statistical comparisons were performed using paired
Wilcoxon signed-rank test with a bonferroni correction for 2
comparisons (oral to single rectal, single to multiple rectal),
resulting in a critical p-value of 0.025 (0.05/2). Standard error (SE,
standard deviation) was a measure of uncertainty around
parameter estimates. Relative standard error (RSE) was a measure
of overall goodness of fit (0 would be a perfect fit).
Results
Demographics
There were a total of 18 subjects included in this analysis.
(Table 1) Mean age was 41, 78% were male, and 84% white. For
oral dosing, the following data were used for pharmacokinetic
analysis: 139 plasma samples, 131 PBMC samples, 149 rectal
tissue homogenates, 72 rectal tissue isolated MMC samples, 31
vaginal sponges, and 135 rectal sponges. For topical dosing, the
following data were used for pharmacokinetic analysis: 228 plasma
samples, 210 PBMC samples, 144 rectal tissue homogenates, 69
rectal tissue isolate MMC sample, 46 vaginal sponges, and 224
rectal sponges. For the purpose of concentration correlation
analysis across matrices only, BLQ samples were excluded. Thus,
163 plasma, 319 PBMC, 208 rectal tissue homogenate, 107 rectal
tissue MMC, 42 vaginal sponge, and 130 rectal sponge samples
were excluded. All pharmacokinetic data are summarized in
Table 2 and Figures 2 and 3. Matrix comparisons are presented in
Figures 4–8.
Plasma Pharmacokinetics
As expected, systemic TFV exposure, measured by both AUC24 h
and Cmax, was 24–33 fold higher after a single oral dose (median
AUC24 h 2200 ng/mL6h, median Cmax 250 ng/mL) than after a
single rectal dose (median AUC24 h 66 ng/mL6h, median Cmax
11 ng/mL). An accumulation ratio of 0.73 demonstrated that there
was no clinically relevant difference in plasma exposure between
single and multiple rectal dosing. A 24-fold lower Cmax was achieved
approximately 1.5 h faster with rectal dosing than with oral dosing
(median Tmax single rectal = 0.32 h versus single oral = 1.9 h;
Table 2). TFV half-life was noted to be at least 5 h shorter (paired t-
test on log-transformed half-lives, p = 0.02) for single and multiple
rectal dosing (4.6–6.6 h) compared to oral dosing (11 h). (Table 2;
Figure 3) Inter-individual variability of the PK parameters (CV%)
ranged from 31–100% during oral dosing, 55–106% during single
rectal dosing, and 53–103% during multiple rectal dosing. Tmax was
the most variable PK parameter with CV% consistently above
100%.
PBMC
No detectable TFVdp was found in total PBMCs after single
and multiple rectal dosing. (Table 2) In contrast, PBMC exposure
after oral dosing was consistently detected in most (10/18) subjects
(median AUC24 h 4.3 fmol/10
6 cells6h, median Cmax 0.38 fmol/
106 cells). There was insufficient data to perform NCA on CD4-
and CD4+ cell subpopulations; please see companion paper
(Richardson-Harmon et.al) for exposure-response analysis.
Figure 4. Increasing TFV in Rectal Tissue Homogenate results in increased TFVdp. There is a linear correlation between rectal tissue
homogenate TFVdp and TFV (p = 0.04, robust RSE = 0.37) with oral dosing only (solid line is mean prediction of TFVdp in rectal tissue from oral
dosing). Shaded regions are the 10–90% confidence intervals of the mean predictions from robust linear regression model. There is no correlation
during rectal dosing.
doi:10.1371/journal.pone.0106196.g004
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Figure 5. Rectal tissue exposure to TFV and TFVdp (median ± IQR) is higher during rectal dosing with multiple rectal dosing,
resulting in accumulation of TFVdp. Each set of figures documents the 30 min drug quantification in the left-side graph and the 24 hr in the
right side graph in rectal tissue biopsy homogenate (5A, 5B) and isolated mucosal mononuclear immune cells (MMC) (5C). Comparisons performed
with paired Wilcoxon signed-rank test; only a subset of patients gave both C30 min and C24 h samples. Figure S5A = TFVTissue; Figure S5B =
TFVdpTissue; Figure S5C = TFVdpMMC. There is accumulation of TFV and TFVdp from multiple rectal dosing. Critical p for significance was 0.025 after
Bonferroni correction.
doi:10.1371/journal.pone.0106196.g005
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Rectal Tissue
There was a linear relationship (p = 0.04) between TFVdp and
TFV in rectal tissue homogenates during oral dosing. This
relationship can be seen in Figure 4. The resulting model (6
standard error) was as follows: Rectal Tissue homogenate TFVdp
concentration (fmol/mg) = 2.37 (60.168)+0.366 (60.121)6rectal
tissue homogenate TFV concentration (ng/mg). Although rectal
data from topical dosing was excluded from the model due to
nonsignificance, they are overlaid in Figure 4 for reference.
Population composite AUC showed that topical dosing resulted
in 2-log10 higher rectal exposure to TFV (single oral vs. single
rectal dose AUC24 h = 0.79 vs. 70 ng/mg6h, Table 2) and a 4-
log10 higher rectal exposure to TFVdp (single oral vs. rectal dose
AUC24 h = 0.24 vs. 5500 fmol/mg 6h). When comparing tissue
concentrations 30 minutes post-dose, single topical dosing resulted
in 2-fold higher TFV (paired p = 0.016) and 4-fold higher (paired
p,0.001) TFVdp concentrations compared to oral dosing
(Figures 4A, 4B). Multiple rectal dosing resulted in a non-
statistically significant 2-fold accumulation in TFV concentrations
compared to single dosing (paired P.0.8), with TFVdp concen-
trations accumulating 4.5-fold (paired p,0.01). Over 24 h, we
observed TFV concentrations continuing to increase after oral
dosing, such that 24 h concentrations post-dose were similar
between oral and topical dosing: median TFV concentration at
24 h was 0.060 ng/mg after oral dosing vs 0.060 ng/mg after
rectal dosing, paired p.0.8). However, median TFVdp concen-
trations 24 h post topical rectal dose were almost 300-fold higher
than after an oral dose, though not statistically significant. (paired
p = 0.125). With 4 subjects having missing paired C24 h rectal
biopsy samples for rectal dosing in Figure 5B, this may have
resulted in biased TFVdp concentrations after topical dosing.
Isolated total mucosal mononuclear cells yielded similar results
to tissue homogenates. At 0.5 h post-dose, rectal dosing resulted in
4-log10 higher concentration (paired p = 0.002) of TFVdp (median
454 fmol/106 cells) compared to oral administration (median
0.010 fmol/106 cells), and remained 4-log10 higher 24 h post dose
(median rectal: 230 fmol/106 cells, oral: 0.010 fmol/106 cells,
Table 2, Figure 5C, paired p = 0.5). There was also accumulation
of TFVdp in these isolated cells after multiple rectal dosing
(accumulation ratio: 2.9, paired p = 0.084).
Regardless of dosing route, compared to plasma, there was large
inter-individual variability in TFV and TFVdp tissue and cell
concentrations at each nominal time. Although no dosing route
was found to have more variable exposure than the other. In tissue
homogenates, TFV CV% ranged from 112–364%, 0 to 220%,
and 236% for single oral, single rectal, and multiple rectal dosing,
respectively. The CV% of TFVdp ranged from 0–307%, 85–
312%, and 132% for single oral, single rectal, and multiple rectal
dosing. The lower CV% of 0 in these groups is a result of all
measured values being below the limit of quantification. The
variability of TFV and TFVdp in isolated mucosal mononuclear
cells was also similarly high regardless of CD4 expression status,
and ranged from 0 to 316%.
Robust linear regression analysis demonstrated that TFVdp in
isolated mucosal mononuclear cells was positively and linearly
correlated with TFVdp in rectal tissue homogenates (Figure 6).
The b3 term (see methods for the initial model) was dropped due
to nonsignificance. Despite a large number of data points (85%)
excluded from the analysis for concentrations below the limit of
Figure 6. TFVdp in rectal tissue homogenate is predictive of intracellular TFVdp concentration in isolated rectal mucosal
mononuclear cells (MMCs), with higher levels of phosphorylation in the CD4+ T cells compared to CD4- T cells. Intracellular TFVdp
concentration in isolated rectal mucosal mononuclear cells increases linearly as TFVdp concentration in rectal tissue homogenate increases. (p,0.001,
robust RSE = 0.46) There is higher phosphorylation of TFV in CD4+ cells, seen in its higher y-intercept. The lines are the mean rectal tissue MMC
TFVdp concentration predictions from robust linear regression model; solid is CD4+, dashed is CD4-. Shaded regions are the 10–90% confidence
intervals of the mean prediction.
doi:10.1371/journal.pone.0106196.g006
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detection, the final model (6 standard error) still achieved
statistical significance (p,0.001), and was as follows: Cellular
TFVdp concentration = 0.680 (60.205) +0.628 (6 0.0818) 6
homogenate TFVdp concentration +0.586 (60.125) 6 cell type
(cell type = 0 for CD4- cells and cell type = 1 for CD4+ cells).
Though there is no interaction between cell type and TFVdp, the
y-intercept of the CD4+ cells was significantly higher (0.680 vs
1.27; p,0.01) than that of the CD4- cells.
Rectal Sponge
TFV exposure in rectal fluid was 1–2 log10 higher during topical
administration (single dose median AUC0–24 h: 1,100,000 ng/g
6h, Cmax 740,000 ng/g, Table 2) compared to oral administra-
tion (median AUC0–24 h: 100,000 ng/g6h, Cmax 9,800 ng/g). As
expected, topical administration achieved maximal concentrations
nearest the time of application (Cmax = 0.38 h). However, oral
administration achieved maximal concentrations 24 hours after
dosing. There was no accumulation of TFV in rectal fluid after
multiple rectal dosing (median AUC24 h single dose 11.0610
5 ng/
g 6h, multiple dose 7.036105 ng/g 6h). Inter-individual
variability was higher for rectal sponge samples compared to
direct sampling of other matrices. With oral dosing, single rectal
dosing, and multiple rectal dosing, TFV concentration CV%
ranged from 150–390%, 92–320%, and 56–150%, respectively.
Robust linear regression demonstrated that plasma TFV
concentrations positively and linearly correlated with TFV in
rectal fluid after topical dosing (Figure 7). No correlation between
plasma concentrations and rectal fluid after oral dosing was noted.
Both b2 and b3 terms were dropped due to nonsignificance, with
the following model (6 standard error) achieving statistical
significance (p,0.001): Plasma TFV =21.23 (60.170) +0.386
(60.0328)6TFV rectal fluid concentration. The number of rectal
doses did not significantly affect these concentration correlations.
Robust linear regression demonstrated that rectal tissue TFV and
TFVdp concentrations positively and linearly correlated with TFV
in rectal fluid, regardless of administration route (Figure 8). Thus,
dose route was dropped as an interaction term. The following model
(6 standard error) achieving statistical significance (p,0.001):
[Rectal Tissue TFV or TFVdp] =b0+b16[Rectal Fluid TFV] For
predicting rectal tissue TFV, b1,TFV = 0.634(60.0777) (p,0.001)
and b0,TFV =22.43(60.335). For predicting rectal tissue TFVdp,
b1,TFVdp = 0.197 (60.0612) (p,0.001), and b0,TFVdp = 1.41
(60.272). Dose route and frequency was not found to be significant
factors in the correlation.
Vaginal Sponge
TFV concentrations in the vaginal lumen peaked at approxi-
mately 3 hours regardless of route of administration. However,
median TFV Cmax in the vagina was approximately 2-fold higher
after a single rectal dose than after a single oral dose (3100 ng/g
vs. 1300 ng/g, Table 2). Additionally, from data in one subject
only, there was evidence of accumulation in the vaginal lumen
after multiple rectal dosing (accumulation ratio = 5).
Less inter-individual variability was seen in the vaginal sponge
data than the rectal sponge data. TFV concentration CV% at each
nominal time from oral dosing, single rectal dosing, and multiple
rectal dosing ranged from 50–140%, 40–120%, and 110–140%,
respectively.
Robust linear regression demonstrated that TFV concentrations
on vaginal sponges are positively and linearly correlated with TFV
concentrations in plasma (Figure 9A). The final predictive model
(6 std error) was: TFV in vaginal fluid = 1.32 (60.0948) +0.778
(60.0704) 6 [plasma TFV] +0.951 (60.169) 6 route. For oral
Figure 7. TFV quantification from rectal sponges is predictive of plasma TFV exposure during rectal dosing. Plasma TFV exposure is
correlated linearly with rectal sponge TFV exposure. (p,0.001, robust RSE = 0.38) The linear correlation is the same regardless of number of rectal
doses. Shaded regions are the 10–90% confidence intervals of the mean predictions from robust linear regression model.
doi:10.1371/journal.pone.0106196.g007
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dosing, route = 0, and for rectal dosing, route = 1. Though there
was no interaction between dose route and TFV in vaginal fluid,
the y-intercept of rectal administration was significantly higher
(2.27 vs. 1.32; p,0.01) than that of oral administration.
Robust linear regression also demonstrated that TFV concentra-
tions on vaginal sponges are positively and linearly correlated with
TFV and TFVdp concentrations in rectal tissue. (Figure 9B) The
final model (6 std error) was as follows: [vaginal fluid TFV] =b0+
b16[TFV or TFVdp in rectal tissue] For TFV in rectal tissue as an
independent predictor of vaginal fluid concentrations, b1,TFV = 0.741
(60.105, p,0.001) and b0,TFV =20.37 (60.402). For TFVdp in
rectal tissue as an independent predictor of vaginal fluid concentra-
tions, b1,TFVdp = 1.66 (60.114, p,0.001), and b0,TFVdp =26.91
(60.649). TFV and TFVdp evaluations were performed as two
Figure 8. TFV (A) and TFVdp (B) concentrations in rectal tissue homogenate are predicted by Rectal Sponge TFV. (p,0.001, robust
RSETFV = 0.67, RSETFVdp = 0.66) Shaded regions are the 10–90% confidence intervals of the mean predictions from robust linear regression model. The
correlations are consistent regardless of administration route and number of doses.
doi:10.1371/journal.pone.0106196.g008
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separate analyses. The coefficients do not directly compare with each
other since the predictor variables are independent and in different
units. Nonetheless, this demonstrates that TFV vaginal fluid
concentrations are significantly linearly correlated with rectal tissue
TFV and TFVdp exposure within the concentration range of 0.10 to
10 ng/mg TFV and 30 to 1000 fmol/mg TFVdp.
Discussion
This is the first study examining the pharmacokinetic distribu-
tion of rectally applied tenofovir gel in various tissues and cells
relevant to HIV infection. This study also compares compartment
concentrations of rectally applied TFV kinetics to oral dosing. It is
important and biologically relevant to quantify TFV and TFVdp
exposures in tissues and cells targeted for HIV infection.
Measuring these concentrations allows for a better understanding
of how drug distributes from the sites of absorption to target
tissues, what factors can impact this distribution, and the possible
identification of less-invasive surrogate markers of exposure that
could be useful in larger clinical trials.
In this study’s intra-subject comparison, the TFV exposure
(AUC24 h) in plasma was, expectedly, more than 30 times higher
after oral administration of 136 mg of TFV equivalent than after
rectal administration of 44 mg of TFV. Additionally, Tmax was
1.6 h shorter with rectal administration than with oral dosing.
Differences in absorption kinetics between the rectum/lower large
intestine and upper small intestine may explain this discrepancy.
The extent and rate of absorption is often lower in the rectum
compared to the intestines. This can be due to the relatively
smaller surface area of the rectum for drug absorption, the
inherent differences in the formulation, and the environment
surrounding the route of administration, such as pH and fluid
content [22–24]. In the particular case of TFV gel, the major
difference is the formulation. Oral TFV is administered as
tenofovir disoproxil fumarate, a di-ester prodrug [25,26]. In
contrast, TFV gel contains only the drug. Thus, TFV gel would
not require the additional metabolism step, leading to a faster
Tmax. The lower plasma exposure after gel dosing is not
completely explained by the lower dose, since the equivalent oral
dose was only 3 times higher. This is most likely due to the lower
extent of drug absorption in the rectum, and also possibly due to
gel leakage.
The half-life of TFV in plasma was 4–6 h longer (p = 0.02) with
oral dosing than with rectal administration, and consistently longer
in all patients except for one. The plasma half-life observed was 1–
3 hours shorter than typically reported [25,26] most likely due to
lack of data in this study during the terminal elimination phase.
Nonetheless, the relative difference in half-life between oral and
rectal administration is significant. One possible explanation is that
the kinetics with rectal dosing may be driven by absorption,
leading to flip-flop kinetics [27]. If this is the true, then the half-life
would be rate-limited by the rate of absorption instead of
elimination. One other explanation may be the saturation of
renal elimination processes [28] as a result of higher TFV plasma
exposure. Tenofovir is eliminated by filtration and secretion [25].
Although renal filtration is not saturable, tubular secretion is
carrier-protein mediated and can exhibit nonlinear, saturable
behavior. During tubular secretion, tenofovir is a substrate for the
MRP4 transporter in the tubular lumen [29–31]. Saturation of this
excretion transporter could explain nonlinear elimination.
In the case of topical administration, the decreased half-life and
lower plasma exposure during both single and multiple adminis-
trations can minimize systemic toxicity. Cmax of TFVdp after a
single oral dose was below limit of detection (LLOQ = 8 fmol/106
cells); this is significantly lower than what has been previously
reported (20 fmol/106 cells [9]), but not unexpected based on
inter-individual variability. This is probably also due to lower cell
penetration of TFV compared to TFVdp. Due to the low plasma
exposure following rectal dosing (median plasma AUC24 h 66 ng/
mL 6h), TFVdp exposure was undetectable in PBMCs of all
subjects.
As expected, rectal tissue exposure to TFV and TFVdp was 2–4
log10 higher with topical administration than with oral dosing.
After multiple dosing, TFV does not appear to significantly
accumulate in the tissue. Although the accumulation ratio from
the median profile showed an approximately 2-fold increase in
AUC24 h, a paired analysis of concentration within individuals
showed no statistically significant changes between the 30 min and
24 h post-dose samples. TFVdp, however, did show significant
accumulation in rectal tissue (approximately 5-fold) and in isolated
mucosal mononuclear cells (approximately 3-fold). The long
intracellular half-life of TFVdp is likely the cause of this tissue
accumulation [32].
It has previously been noted that an increase in TFV tissue
homogenate concentration yields an increase in TFVdp concen-
tration [9,32]. We confirmed this at 24 h after oral dosing
(Figure 4). The correlation may have been stronger if there would
have been more data to analyze. Furthermore, it is possible that
the different absorption kinetics of the rectum compared to the
intestines could cause variations in this correlation.
To address the question of whether TFVdp in tissue homog-
enates accurately reflect TFVdp concentrations in target cells for
HIV transmission, or whether the heterogeneous mix of cells in
mucosal tissue confounds the results, we compared homogenate
results to those of isolated mucosal mononuclear cells. Encourag-
ingly, a linear relationship was noted between TFVdp concentra-
tion in rectal tissue homogenate and isolated mucosal mononu-
clear cells. This linear relationship was not influenced by CD4
status: as TFVdp concentration in the homogenate increased by
100%, there was a 63% increase of TFVdp in the isolated mucosal
mononuclear cells. However, the data did suggest that there may
be differences in phosphorylation based on the CD4 expression
status of the cell. When plotting the relationship between TFVdp
in tissue homogenates and in CD4+ and CD4- cells, the Y
intercept in CD4+ cells was 1.6-fold higher than in CD4- cells.
That is, for every observed TFVdp concentration in the
homogenate, the TFVdp concentration in the CD4+ cells was
1.6-fold higher than CD4- cells. This difference persisted
throughout the 10–10,000 fmol/mg range of TFVdp concentra-
tions, and achieved statistical significance (p,0.01), even with
small numbers of samples. The source of this difference is unclear,
as some studies suggest that tenofovir is phosphorylated to a
similar extent between quiescent and stimulated cells, while others
suggest higher phosphorylation in resting cells [33]. Although it is
currently unknown whether these concentration differences are of
clinical significance, these data are encouraging, as they suggest
that TFVdp is found in higher concentrations in the cells that are
targets for HIV infection.
In this study, rectal mucosal fluid was collected to determine
whether it could be a surrogate for TFV and TFVdp concentra-
tion in rectal tissue. TFV concentrations in the rectal fluid linearly
correlated with rectal tissue TFVdp. (Figure 8) This relationship
remained consistent regardless of dose route or frequency. Despite
dramatic differences between oral and rectal absorption charac-
teristics, we still observe a similar linear relationship between these
two matrices. Therefore, rectal fluid TFV concentrations collected
by sponge are useful in estimating drug concentrations in the
target rectal tissue.
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We also attempted prediction of plasma TFV exposure from
rectal mucosal concentrations. There was high variability in these
predictions, so a precise prediction was not possible. However, our
data suggest that a rough estimation of high or low plasma TFV
based on rectal TFV concentration could be feasible. Therefore,
rectal sponge TFV concentration could be used as a non-invasive
surrogate for plasma TFV concentrations for safety and toxicity
monitoring. With more patient data, prediction variability may be
decreased using patient demographic covariates, which could
potentially minimize the need for blood sampling in future trials of
Figure 9. There is vaginal penetration of TFV from both oral and topical rectal exposures. (A) Vaginal fluid detection of both TFV and
TFVdp concentration in vaginal fluid is higher following rectal dosing than following single oral dosing TFVdp. There is a linear correlation between
vaginal fluid sponge TFV and plasma TFV concentrations (p,0.001, robust RSE = 0.44). TFV penetration into vaginal fluid is 1-log10 higher with rectal
administration than oral, seen with higher y-intercept. (p,0.001). (B) There is a linear correlation between vaginal fluid TFV and both rectal tissue TFV
and TFVdp (p,0.01, robust RSETFV = 0.47, RSETFVdp = 0.13). Shaded regions are the 10–90% confidence intervals of the mean predictions from robust
linear regression model. Solid line is mean vaginal fluid TFV concentration, dashed TFVdp.
doi:10.1371/journal.pone.0106196.g009
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rectal dosing. We did not observe similar correlation with oral
dosing; this is probably due to the high variability in the data
compared to the possible strength of the correlation. If we had a
higher range of rectal fluid concentration, through either different
oral dose levels or sample collection times, then it is possible a
correlation may be observed.
Previous data in macaques has demonstrated that 5–7% of
tenofovir dosed rectally can be found in vaginal fluid [34]. We
evaluated this phenomenon in 4 women, and found that vaginal
concentrations were 8.7% of rectal secretion concentrations
sampled at the same time, similar to the 1–2 log10 difference
found previously in animals. Additionally, we noted a 1.6-fold
higher exposure of TFV in vaginal secretions with rectal dosing
than with oral dosing. Since the slopes of the relationship between
vaginal fluid TFV and plasma TFV with the two administration
routes are not significantly different, the rate of TFV penetration
into the vagina does not vary with administration route. As plasma
concentrations with oral dosing are much higher than with rectal
dosing, systemic re-distribution into the vaginal fluid cannot be the
only mechanism by which TFV reaches the vaginal lumen.
Vaginal TFV penetration was further confirmed when we
observed a linear relationship between vaginal TFV exposure
and rectal tissue exposure. When rectal tissue TFV and TFVdp
exposure increased, there was also a linear increase in vaginal
exposure to TFV. Due to the low number of data points, we could
not discern whether route of administration affected this relation-
ship.
It is interesting to note that there was accumulation of TFV in
the vaginal fluid (Table 2, single rectal dose AUC = 1.4 ng/g6h,
multiple rectal dose = 11), but not rectal fluid (single rectal dose
AUC = 11 ng/g6h, multiple rectal dose = 7.0). There are two
possible explanations for this. One is that the rectal site is already
saturated due to proximity to administration, whereas vaginal site
is more distal and takes time to build up. Another is that there may
be differences in fluid turnover between the two sites. Therefore,
the kinetics is inherently different between the two sites.
One limitation of this analysis is the treatment of BLQ values
and nominal times used for the composite PK profiles in Table 2.
BLQ numbers are still valuable because there is a lot of
information content in these numbers. Therefore, the treatment
of BLQ values depended on the analysis performed. They are
imputed as 0.01 for NCA, and ignored for correlation analysis due
to statistical difficulties in treating these numbers. Since this was
done systematically and consistently, there should be no impact on
the overall conclusions. Also, the proportion of BLQ values for
plasma was low (2.4%), so this should have little impact on the
calculated plasma PK parameters. Similarly, since only datapoints
that fell within a specific time window were included in the
composite profiles, there should not have been a significant bias in
PK parameter estimates.
Conclusion
This was the first comprehensive pharmacokinetic study of
rectally administered tenofovir gel that describes the distribution of
TFV and TFVdp into various tissue compartments relevant to
HIV infection. The compartments included rectal fluid, rectal
tissue and its isolated mucosal mononuclear cells, vaginal fluid,
blood plasma and PBMCs. It was expected, and now confirmed,
that rectally applied TFV would have lower systemic exposure and
higher vaginal exposure compared to oral. There was accumula-
tion of TFVdp in the rectal tissue, due to the long intracellular
half-life. An unexpected yet biologically interesting finding was
detecting a consistent difference in concentrations of TFVdp in
rectal mucosal CD4+ cells, prime targets for new HIV infections.
It is useful to know that TFV rectal fluid concentrations may be
reasonable bio-indicators of plasma and, importantly, rectal tissue
concentrations, making it easier to estimate adherence and TFV
concentrations in the target tissue.
We were encouraged to see many concentration correlations
across various relevant matrices, such as rectal mucosal mononu-
clear cells and rectal tissue homogenate TFVdp, and vaginal fluid
and plasma. This will enable more advanced population
pharmacokinetic modeling methods and developing a single
mathematical model that describes the distribution of TFV with
more accuracy. Furthermore, if target TFV and TFVdp concen-
trations are identified, then these data and models will assist in
dose/regimen selection that maximizes efficacy and minimizes
toxicity.
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